What is Oxitec?
Oxitec operates at the intersection of biotechnology and public health, specializing in the development of non-biting male mosquitoes designed to suppress populations of Aedes aegypti. By leveraging advanced genetic engineering, the company provides a sustainable alternative to traditional chemical-based insect control. Its technology is uniquely engineered to prevent environmental persistence and avoid harm to non-target species, such as pollinators. With proven efficacy in urban environments—demonstrating up to 95% suppression rates in field trials—Oxitec is positioned to disrupt the vector control market by reducing operational costs by up to 90% compared to conventional release programs. The company's market position is defined by its ability to provide scalable, environmentally responsible solutions for dengue, Zika, and malaria-prone regions.
How much funding has Oxitec raised?
Oxitec has raised a total of $35.2M across 5 funding rounds:
Private Equity
$2.6M
Private Equity
$3M
Private Equity
$12.6M
Private Equity
$10.2M
Private Equity
$6.8M
Private Equity (2005): $2.6M with participation from East Hill Management Company, LLC, Oxford University, and Oxford Capital Partners
Private Equity (2007): $3M led by East Hill Management Company, LLC and Oxford Capital Partners
Private Equity (2012): $12.6M supported by Asia Pacific Capital and Oxford Capital Partners
Private Equity (2014): $10.2M featuring East Hill Management, Oxford Capital Partners, and Oxford University
Private Equity (2021): $6.8M backed by The Wellcome Trust
Key Investors in Oxitec
East Hill Management
A Boston-based investment advisory firm managing alternative assets for high-net-worth individuals and non-profit endowments, with a specific focus on life sciences and academic spinouts.
Oxford Capital Partners
An Oxford-based investment manager providing growth capital to smaller companies across diverse industries, with a focus on helping entrepreneurs scale their businesses.
The Wellcome Trust
An independent global charitable foundation based in London that supports discovery research and tackles urgent health challenges through grants, partnerships, and advocacy.
What's next for Oxitec?
With the support of major enterprise-level funding, Oxitec is poised to accelerate the global deployment of its vector control platform. The strategic focus remains on scaling production capabilities and expanding into new geographies where Aedes aegypti poses a significant public health threat. By optimizing its release technology and continuing to demonstrate long-term environmental safety, the company aims to solidify its role as a critical partner for governments and health organizations. Future growth will likely center on integrating these biological innovations into broader public health infrastructure, ensuring that the company remains at the forefront of sustainable, technology-driven disease prevention.
See full Oxitec company page
